The latest price target for Veracyte (NASDAQ:VCYT) was reported by UBS on February 25, 2025. The analyst firm set a price target for $49.00 expecting VCYT to rise to within 12 months (a possible 43.23% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by UBS, and Veracyte maintained their buy rating.

There is no last upgrade for Veracyte

The last downgrade for Veracyte Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $38 to $37 for Veracyte Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on February 25, 2025 so you should expect the next rating to be made available sometime around February 25, 2026.

While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a maintained with a price target of $46.00 to $49.00. The current price Veracyte (VCYT) is trading at is $34.21, which is out of the analyst’s predicted range.